Clinical Trial Update: B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating B cell maturation antigen (BCMA) targeted CAR-T cells for relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-targeted CAR-T cells

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Multiple Myeloma, Relapse Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN